Anlotinib is a small-molecule multi-targeted targeted agent, and generally a box of seven capsules can be taken for a week, one capsule per day, which is a relatively standard treatment regimen. However, the main indication of Anrotinib is for third-line targeted therapy for non-small cell lung cancer. Other malignancies, such as small cell lung cancer, can also be treated with Anrotinib. Other malignancies such as breast cancer, pancreatic cancer, etc., may also be treated with anlotinib, but there are no approved indications for it yet, so it can only be tried. The use of Anrotinib should be monitored for skin allergies, liver function impairment, blood pressure changes and other side effects, and generally take a week off for two weeks to rest.